PROJECT CONSULTING

Consulting

Our expertise in the development of cutting-edge strategies for phage display peptide and antibody discovery spans over 30 years. Our wide range of consultancy services provides comprehensive support regarding affinity selections, peptide and antibody screening, affinity maturation, and more.

LETS TALK

Accelerate Your Research Project

Phage display technology is a potent technology employed in drug discovery to develop peptides and monoclonal antibodies that specifically and strongly bind to target molecules. Its applications span various stages of drug development, encompassing peptide and antibody discovery, drug candidate screening, and lead optimization. Researchers can screen phage display libraries using different biopanning methodologies to suit their requirements. However, the lack of a tailored phage display selection strategy often leads to peptides and antibodies with suboptimal pharmacokinetic properties that lack high binding affinity and specificity.

Our Expertise in Phage Display Research Strategies

At Cell Origins, our expertise spans over 30 years in the development of cutting-edge strategies for phage display, peptide and antibody discovery, and ligand optimization. With a team of industry-leading experts in phage display and drug discovery, we are dedicated to ensuring the success of your project. Our wide range of consultancy services provides comprehensive research strategies and protocols tailored to your needs, enabling the selection of high-affinity peptides and antibodies with exceptional pharmacokinetic profiles through customized phage display. Additionally, we offer expert guidance on lead optimization, enhancing binding kinetics, off-target binding profiles, and tissue excretion redirection for your existing peptides and antibodies. Our research strategies have contributed to numerous impactful publications, projects, and research grants.

Our Team at Cell Origins

The founders of Cell Origins received their training at the University of Missouri, where phage display technology was pioneered. Our scientists have published numerous research articles, including ones cited by Dr. George Smith in his Nobel Prize lecture. Our team of scientists leverages cutting-edge approaches to unlock the full potential of phage display, ensuring success for your research project.

We are a contract research organization and development company with a proven track record in the field of phage display. Let our experienced team help you develop a strategy that optimizes results and provides the best solution for your research needs.

Contact Us to Get Started

At our core, we are dedicated to delivering excellent service that guarantees the success of your project. To begin this journey, please schedule a consultation so we can learn more about your research requirements and how we can assist you. Our commitment lies in aiding you to receive the most effective solution for your project, propelling your research process forward. Reach out to us today to expand your horizons and schedule a meeting with one of our experienced scientists.

Let's Get Started!

At Cell Origins, we are here to help with your phage display and drug discovery projects. Whether you're looking to have our experts develop a biopanning protocol or need an extra team member for a long term project, we are here to support you at each step. We collaborate closely with you to create customized strategies. Our most popular consulting services include the development of affinity selection and affinity maturation protocols to identify and improve the binding kinetics of peptides and antibodies, as well as strategies to ensure that lead molecules not only have high binding affinity, but also demonstrate excellent pharmacokinetics. However, we are here to tackle any project so you can accelerate your peptide and antibody discovery projects. Our dedicated team of experts is here to provide comprehensive support and feedback for the duration of your project. Contact us to get Cell Origins on your team.

LETS TALK

Published Work

Axiak-Bechtel, S. M., Leach, S. B., Scholten, D. G., Newton-Northup, J. R., Johnson, B. J., Durham, H. E., Gruber, K. A., Callahan, M. F. (2021). Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogs. Pharmacology Research & Perspectives. Vol. 9(3)

Asar, M., Franco, A., Soendergaard, M. (2020). Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides. Biomolecules. 10(5), 714

Asar, M., Gunby, T., Franco, A., Woodson, C., Soendergaard, Mette. (2020). Identification of an Indiscriminate Peptide by Phage Display Technology. The FASEB Journal 34:1_supplement, 1-1
More

Asar, M., Newton-Northup, J., Deutscher, S., Soendergaard, M. (2019). Ovarian Cancer Targeting Phage for In Vivo Near-Infrared Optical Imaging. Diagnostics, 9, 183.

Newton-Northup, J.R., and Deutscher, S.L. (2017). Bacteriophage for the Development of Novel Tumor-Targeting Agents with Specific Pharmacokinetics and Imaging Applications. Methods in Molecular Biology in Biosensors and Biodetection.

Newton-Northup, J.R., and Deutscher, S.L.. (2016). Cytotoxic Tumor-Targeting Peptides From In Vivo Phage Display. Combinatorial Chemistry & High Throughput Screening. Vol. 19(5): 370–377

García, M. F., Zhang, X., Shah, M., Newton-Northup, J., Cabral, P., Cerecetto, H., and Quinn, T. (2016). 99mTc-bioorthogonal click chemistry reagent for in vivo pretargeted imaging. Bioorganic & Medicinal Chemistry. Vol. 24(6): 1209–1215

Newton-Northup, J.R., Dickerson, M.T., Kumar, S.R., Smith, G.P., Quinn, T.P., And Deutscher, S.L. (2014) In vivo bacteriophage peptide display to tailor pharmacokinetics of biological nanoparticles. Molecular Imaging and Biology. 16(6), 854-864.

Soendergaard M., Newton-Northup J. R., Deutscher S. L. (2014): In Vivo Phage Display Selection of an Ovarian Cancer Targeting Peptide for SPECT/CT Imaging. American Journal of Nuclear Medicine and Molecular Imaging. 4(6): 561–570.

Soendergaard, M., Newton-Northup, J.R., and Deutscher, S.L. (2014) In vitro high throughput phage display selection of ovarian cancer avid phage clones for near-infrared optical imaging. Combinatorial Chemistry and High Throughput Screening. 17(10).

Newton-Northup, J.R., and Deutscher, S.L. (2013). Contending With Target Unrelated Peptides from Phage Display. Journal of Molecular Imaging & Dynamics. Vol. 2(2):

Newton-Northup, J. R., Dickerson, M. T., Ma, L., Besch-Williford, C. L., Deutscher, S. L. (2013). Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide. Clinical & Experimental Metastasis. Vol. 30:119–132

Newton-Northup, J.R., and Deutscher, S.L. (2012) Contending with target unrelated peptides from phage display. Journal of Molecular Imaging and Dynamics. 2(2).

Soendergaard, M., Newton-Northup, J.R., Palmier, M.O., and Deutscher, S.L. (2011) Peptide phage display for discovery of novel biomarkers for imaging and therapy of cell subpopulations in ovarian cancer. Journal of Molecular Biomarkers and Diagnosis, S:2.

Newton-Northup, J.R., Figueroa, S.D., and Deutscher, S.L. (2010). Streamlined in vivo selection and screening of human prostate carcinoma avid phage particles for development of peptide based in vivo tumor imaging agents. Combinatorial chemistry & high throughput screening. 14(1):9-21

Deutscher, S. L., Dickerson, M., Gui, G., Newton, J., Holm, J. E., Vogeltanz-Holm, N., Kliethermes, B., Hewett, J. E., Kumar, S. R., Quinn, T. P., Sauter, E. R. (2010). Carbohydrate antigens in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy. BMC Cancer. Vol. 10(519)

Newton-Northup, J.R., Figueroa, S.D., Quinn, T. P., and Deutscher, S.L. (2009). Bifunctional phage-based pretargeted imaging of human prostate carcinoma. Nuclear Medicine and Biology. Vol. 36(7):789-800

Jin, X., Newton, J. R., Montgomery, S., Smith, G. P. (2009). A generalized kinetic model for amine modification of proteins with application to phage display. Biotechniques. Vol. 46(3):175-182

Newton-Northup, J.R., and Deutscher, S.L. (2009). In vivo bacteriophage display for the discovery of novel peptide-based tumor-targeting agents. Methods in Molecular Biology. Vol. 504:275-90.

Newton-Northup, J.R., and Deutscher, S.L. (2008). Peptide Phage Display. Handbook of Experimental Pharmacology: Molecular Imaging I. Vol. 185 Pt 2:145-163.

Newton, J. R., Miao, Yubin., Deutscher, S. L., and Quinn, T. P. (2007). Melanoma Imaging with Pretargeted Bivalent Bacteriophage. Journal of Nuclear Medicine. Vol. 48(3):429-436

Newton, J. R., Kelly, K. A., Mahmood, U., Weissleder, R., and Deutscher, S. L. (2006) In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia. 8(9), 772-780.